Dr. Donald Wender
Claim this profileSiouxland Regional Cancer Center
Area of expertise
Lung Cancer
Donald Wender has run 7 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Donald Wender has run 6 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Siouxland Regional Cancer Center
June E. Nylen Cancer Center
Clinical Trials Donald Wender is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting
2 awards
Phase 3
2 criteria
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting
2 awards
Phase 3
4 criteria
More about Donald Wender
Clinical Trial Related
7 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Donald Wender has experience with
- Carboplatin
- Nivolumab
- Cisplatin
- Pembrolizumab
- Lenalidomide
- Rituximab
Breakdown of trials Donald Wender has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Donald Wender specialize in?
Donald Wender focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage II.
Is Donald Wender currently recruiting for clinical trials?
Yes, Donald Wender is currently recruiting for 8 clinical trials in Sioux City Iowa. If you're interested in participating, you should apply.
Are there any treatments that Donald Wender has studied deeply?
Yes, Donald Wender has studied treatments such as Carboplatin, Nivolumab, Cisplatin.
What is the best way to schedule an appointment with Donald Wender?
Apply for one of the trials that Donald Wender is conducting.
What is the office address of Donald Wender?
The office of Donald Wender is located at: Siouxland Regional Cancer Center, Sioux City, Iowa 51101 United States. This is the address for their practice at the Siouxland Regional Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.